BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 32744691)

  • 1. Gemcitabine combined with cisplatin vs. taxane, cisplatin, and fluorouracil in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective case-control study.
    Huang YM; Qiao SQ; Lu L; Chen WP; Li SL; Qi CH
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(14):7655-7663. PubMed ID: 32744691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis.
    Liu GY; Lv X; Wu YS; Mao MJ; Ye YF; Yu YH; Liang H; Yang J; Ke LR; Qiu WZ; Huang XJ; Li WZ; Guo X; Xiang YQ; Xia WX
    Cancer Commun (Lond); 2018 May; 38(1):21. PubMed ID: 29764487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of GP and TPF induction chemotherapy for locally advanced nasopharyngeal carcinoma.
    Zhu J; Duan B; Shi H; Li Y; Ai P; Tian J; Chen N
    Oral Oncol; 2019 Oct; 97():37-43. PubMed ID: 31421469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma.
    Chen R; Lu Y; Zhang Y; He R; Tang F; Yuan W; Li Y; Zhang X
    Medicine (Baltimore); 2021 Oct; 100(42):e27475. PubMed ID: 34678878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.
    Zhou R; Zhu J; Chen X; Liu Y; Wang Y; Zhang T
    Clin Transl Oncol; 2020 Mar; 22(3):429-439. PubMed ID: 31165410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of adding PD-1 blockade to induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) for locoregionally advanced nasopharyngeal carcinoma: an observational, propensity score-matched analysis.
    Jin YN; Qiang MY; Wang Y; Lin YJ; Jiang RW; Cao WW; Zhang WJ; Wang SY; Zhang HY; Yao JJ
    Cancer Immunol Immunother; 2024 May; 73(7):125. PubMed ID: 38733402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival benefit of adding docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma with nodal Stage N2-3.
    Kawahira M; Yokota T; Hamauchi S; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H
    Jpn J Clin Oncol; 2017 Aug; 47(8):705-712. PubMed ID: 28431119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment and Survival Outcomes Associated With Platinum Plus Low-Dose, Long-term Fluorouracil for Metastatic Nasopharyngeal Carcinoma.
    Zheng SH; Liu SR; Wang HB; Wei YH; Li H; Wang GN; Huang ZL; Ding SR; Chen C; Tao YL; Li XH; Glorieux C; Huang P; Wu YF; Xia YF
    JAMA Netw Open; 2021 Dec; 4(12):e2138444. PubMed ID: 34902036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as a first-line concurrent chemotherapy regimen in nasopharyngeal carcinoma: a prospective, multi-institution, randomized controlled phase II study.
    Kong XY; Lu JX; Yu XW; Zhang J; Xu QL; Zhang RJ; Mi JL; Liao SF; Fan JF; Qin XL; Yao DC; Tang HY; Jiang W
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):155-161. PubMed ID: 31087135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel and cisplatin induction chemotherapy with or without fluorouracil in locoregionally advanced nasopharyngeal carcinoma: A retrospective propensity score matching analysis.
    Tao HY; Zhan ZJ; Qiu WZ; Liao K; Yuan YW; Zheng RH
    Asia Pac J Clin Oncol; 2022 Apr; 18(2):e111-e118. PubMed ID: 33945215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine and cisplatin versus docetaxel and cisplatin as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma from non-endemic area of China.
    Zang J; Xu M; Li C; Zhao L; Luo S; Wang J; Shi M
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2369-2378. PubMed ID: 32363479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of efficacy and safety of three induction chemotherapy regimens with gemcitabine plus cisplatin (GP), cisplatin plus fluorouracil (PF) and cisplatin plus capecitabine (PX) for locoregionally advanced previously untreated nasopharyngeal carcinoma: A pooled analysis of two prospective studies.
    Chan SK; Chan SY; Tong CC; Lam KO; Kwong DL; Leung TW; Luk MY; Lee AW; Choi HC; Lee VH
    Oral Oncol; 2021 Mar; 114():105158. PubMed ID: 33508707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety and efficacy of gemcitabine and cisplatin (GP)-based induction chemotherapy plus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.
    Tang M; Jia Z; Zhang J
    Eur Arch Otorhinolaryngol; 2022 Mar; 279(3):1561-1572. PubMed ID: 34259896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing three induction chemotherapy regimens for patients with locoregionally advanced nasopharyngeal carcinoma based on TNM stage and plasma Epstein-Barr virus DNA level.
    Liu SL; Sun XS; Xie HJ; Chen QY; Lin HX; Liang H; Liang YJ; Li XY; Yan JJ; Lin C; Yang ZC; Guo SS; Liu LT; Tang QN; Du YY; Tang LQ; Guo L; Mai HQ
    BMC Cancer; 2020 Feb; 20(1):89. PubMed ID: 32013967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
    Wei Z; Zhang Z; Luo J; Li N; Peng X
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term outcomes of induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF) in locally advanced nasopharyngeal carcinoma.
    Takamizawa S; Honma Y; Murakami N; Mori T; Oka H; Yamamoto S; Kashihara T; Ito K; Kubo Y; Ikeda A; Matsumoto F; Omura G; Kobayashi K; Itami J; Kato K; Yoshimoto S
    Invest New Drugs; 2021 Apr; 39(2):564-570. PubMed ID: 32940872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of gemcitabine plus cisplatin versus docetaxel, cisplatin and fluorouracil for induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma.
    Wu Q; Liao W; Huang J; Zhang P; Zhang N; Li Q
    Oral Oncol; 2020 Apr; 103():104588. PubMed ID: 32070923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.
    Kong L; Zhang YW; Hu CS; Guo Y
    Chin J Cancer; 2010 May; 29(5):551-5. PubMed ID: 20426907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential chemoradiotherapy with gemcitabine and cisplatin for locoregionally advanced nasopharyngeal carcinoma.
    Gu MF; Liu LZ; He LJ; Yuan WX; Zhang R; Luo GY; Xu GL; Zhang HM; Yan CX; Li JJ
    Int J Cancer; 2013 Jan; 132(1):215-23. PubMed ID: 22610788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction chemotherapy for the treatment of non-endemic locally advanced nasopharyngeal carcinoma.
    Zhao L; Xu M; Jiang W; Pan H; Zang J; Luo S; Wang J; Zhou Y; Shi M
    Oncotarget; 2017 Jan; 8(4):6763-6774. PubMed ID: 28036270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.